The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee reviewed a biologics license application for vusolimogene oderparepvec, an investigational gene therapy developed by Replimune. The therapy is intended to be used in combination with nivolumab for adults with advanced melanoma whose cancer has continued to progress despite treatment with anti-PD-1 immunotherapy.
The treatment works by using a genetically modified virus to selectively infect and destroy cancer cells while stimulating the body's immune system to recognize and attack tumors more effectively. Researchers hope this dual approach will improve outcomes for patients who have limited treatment options after standard therapies fail.
Although the advisory committee's recommendation is not legally binding, the FDA often considers such expert opinions when making its final regulatory decision. A positive recommendation significantly strengthens the therapy's prospects and represents an important step toward expanding treatment options for advanced melanoma patients.
Melanoma is among the most aggressive forms of skin cancer, particularly once it spreads to other organs. Health experts say continued advances in gene therapy and immunotherapy are transforming cancer care by providing more targeted treatments that harness the patient's own immune system to fight disease.
